Fig. 7
From: Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia
CEBPA mutations must precede mutations in CSF3R for AML initiation. a Diagram of order of acquisition system. Oncogenes in the MIG vector tagged with GFP are constitutively expressed and oncogenes in the idsRed vector are expressed only after Cre mediated recombination. Expression of the second oncogene can be induced by administration of tamoxifen. Mice were administered 75,000 GFP/RFP-positive cells. b Survival reported as time from day 1 of tamoxifen induction (n = 5/group). Statistical significance calculated by Log Rank test, **p < 0.01. c Expression of CD11b and GR-1 in bone marrow at 5 weeks in moribund CEBPAV314VW-first mice, healthy CSF3RT618I-first mice or at 7-weeks in leukemic CSF3RT618I-first mice (only one animal represented by CSF3R-first leukemia, others are representative of 3/group). d Manual differentials of peripheral blood from mice 5 weeks after tamoxifen induction (n = 3/group), **p < 0.01, ****p < 0.0001. e Representative bone marrow histology (scale bar represents 10 μm). f Spleen weight of mice sacrificed at 5 weeks post tamoxifen treatment, *p < 0.05 as calculated by Student’s T-test g Representative spleen histology (scale bar represents 100 μm for upper panels and 20 μm for lower panels). In all cases, values are represented as mean with error bars representing SEM. Source data are provided as a Source Data file.
